MTOR and acute myeloid leukemia: Therefore, in addition to the “monocyte-like”, partially differentiated AML cells that survive cytarabine chemotherapy and exhibit high CD36 expression [43], there exist conditions under which AML cells with suppressed CD36 expression and suppressed mTOR activity can reinitiate AML after treatment, such as the CD69-expressing quiescent HSC-like AML cells.